Streetbeat News

Products Services

OVID

TAK

Takeda's Phase 3 topline study results for Soticlestat have led Ovid Therapeutics to prioritize and pursue its programs with financial discipline. Ovid expects its cash runway to last into the first half of 2026.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 11:01 am

TAK

Takeda announced that its Phase 3 studies of Soticlestat (TAK-935) for Dravet Syndrome and Lennox-Gastaut Syndrome missed their primary endpoints. Despite this, the studies showed clinically meaningful effects in secondary endpoints and a favorable safety profile. Takeda plans to discuss the data with regulatory authorities.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 10:48 am

AZN

The FDA has approved AstraZeneca's cancer drug Imfinzi (durvalumab) for treating advanced endometrial cancer with mismatch repair deficiency (dMMR). The approval is based on the DUO-E Phase III trial, which showed a 58% reduction in disease progression or death when Imfinzi was used with chemotherapy. AstraZeneca aims to increase its revenue significantly by 2030 through its oncology and other portfolios.

Portfolio Pulse from Shivani Kumaresan

June 17, 2024 | 10:38 am

AMZN

GOOGL

MSFT

A coalition of 26 European industry groups has called for a non-discriminatory approach to the proposed EU Cybersecurity Certification Scheme (EUCS) for cloud services, urging that tech giants like Microsoft, Google, and Amazon should not be discriminated against. The EUCS aims to help governments and businesses select secure cloud service providers. The industry groups emphasize that an inclusive EUCS will support the free movement of cloud services in Europe, contributing to digital ambitions and security resilience.

Portfolio Pulse from Benzinga Neuro

June 17, 2024 | 10:37 am

BTCUSD

ETHUSD

XRPUSD

Bloomberg ETF analyst Eric Balchunas has moved up the launch date for the highly anticipated spot Ether ETF to July 2, following light comments from the SEC on S-1 filings. This adjustment could serve as a new catalyst for market dynamics, especially in the digital asset market, which has recently seen significant outflows.

Portfolio Pulse from Murtuza Merchant

June 17, 2024 | 10:30 am

AAPL

AMZN

GOOG

IWM

LULU

META

MSFT

NVDA

SNOW

Nvidia's dominance in the AI sector is drawing investments away from other sectors and stocks, causing declines even in fundamentally sound companies. This phenomenon is impacting the broader market, with tech stocks like Nvidia, Alphabet, Amazon, Apple, Microsoft, and Meta driving the current rally. The iShares Russell 2000 ETF, which tracks small-cap stocks, is down for the year, highlighting the narrow breadth of the market rally.

Portfolio Pulse from Shanthi Rexaline

June 17, 2024 | 10:17 am

KROS

Keros Therapeutics presented additional data from its ongoing Phase 2 trials of Elritercept (KER-050) for myelodysplastic syndromes and myelofibrosis. The data showed durable transfusion independence and improvements in patient-reported fatigue measures for lower-risk myelodysplastic syndromes. In myelofibrosis, Elritercept demonstrated benefits in hematopoiesis, cytopenias, spleen volume reduction, and symptom scores.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 10:05 am

FBTC

GBTC

IBIT

Financial advisors are cautious in adopting Bitcoin ETFs despite significant interest from self-directed investors, hedge funds, and brokerages. BlackRock's Samara Cohen highlights the need for thorough risk analysis and due diligence due to Bitcoin's price volatility and regulatory concerns. Notable Bitcoin ETFs include BlackRock’s iShares Bitcoin Trust (NASDAQ:IBIT), Grayscale Bitcoin Trust (NYSE:GBTC), and Fidelity’s Wise Origin Bitcoin Trust (BATS:FBTC).

Portfolio Pulse from Benzinga Neuro

June 17, 2024 | 10:03 am

ZYME

The FDA has cleared Zymeworks' Investigational New Drug (IND) application for ZW171, a treatment for mesothelin-expressing cancers. The company plans to begin clinical development of ZW171 in 2024.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 10:03 am

EQNR

EWQ

Equinor and GRTgaz have signed a project development agreement to create a CO2 transport system for captured CO2 from industrial emitters in France to offshore storage in Norway via the CO2 Highway Europe pipeline project.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 9:55 am